Last reviewed · How we verify
Rocklatan
Rocklatan, marketed by Colorado Ophthalmology Associates PC, is an ophthalmic solution currently available in the market. The key composition patent for Rocklatan is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Rocklatan |
|---|---|
| Sponsor | Colorado Ophthalmology Associates PC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- Rocklatan Retinal Perfusion OCT Study (PHASE4)
- Next Generation Rocklatan (PHASE2)
- Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) (PHASE4)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |